The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

Bioresorbable scaffolds: reflections after a setback - losing a battle does not mean losing the war!

EuroIntervention 2017;13:785-786. DOI: 10.4244/EIJV13I7A115

Division of Interventional Cardiology, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy


Recent evidence from the three-year follow-up of the ABSORB II trial1, the two-year data of the ABSORB III trial (Ellis SG et al, presented at the American College of Cardiology 2017 congress, Washington DC, USA), and the Amsterdam Investigator-initiateD Absorb strategy all-comers (AIDA) trial2, has suggested that the Absorb™ (Abbott Vascular, Santa Clara, CA, USA) bioresorbable scaffold (BRS) exhibits inferior performance as compared with the benchmark metallic everolimus-eluting stent (EES) in terms of late luminal loss, target vessel myocardial infarction, and scaffold thrombosis (ST). These facts prompted the manufacturer to halt the commercialisation of the device in Europe with effect ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Focus on the two types of EAPCI fellowships: the one-year fellowship and the μFellowship.